Details for Patent: 6,110,938

Title:	1-(arylthioalkyl, arylaminoalkyl or arylmethylenealkyl)-4-(heteroaryl)piperidines and related compounds useful as antipsychotics and analgesics
Abstract:	Heteroarylpiperidines, pyrrolidines, and piperazines are useful as antipsychotic and analgesic agents. the compounds are especially useful for treating psychoses by administering to a mammal a psychoses-treating effective amount of one of the compounds. Depot derivatives of the compounds are useful for providing long acting effects of the compounds. The compounds are also useful as analgesics by administering a pain-relieving effective amount of one of the compounds to a mammal.
Inventor(s):	Strupczewski; Joseph T. (Flemington, NJ), Chiang; Yulin (Covent Station, NJ), Glamkowski; Edward J. (Warren, NJ), Bordeau; Kenneth J. (Kintnersville, PA), Helsley; Grover C. (Stockton, NJ)
Assignee:	Hoescht Marion Roussel, Inc. (Kansas City, MO)
Filing Date:	Jun 06, 1995
Application Number:	08/471,032
Claims:	1. A compound of the formula: ##STR133## wherein, X is --O--, --S--, --NH--, or ##STR134## R.sub.2 is selected from the group consisting of lower alkyl, aryl lower alkyl, aryl, cycloalkyl, aroyl, alkanoyl, and phenylsulfonyl groups; wherein aryl is as defined hereinafter; p is 1 or2; Y is hydrogen, lower alkyl, hydroxy, chlorine, fluorine, bromine, iodine, lower alkoxy, trifluoromethyl, nitro, or amino, when p is 1; Y is lower alkoxy, hydroxy or halogen when p is 2 and X is --O--; in which (R.sub.1) is R.sub.20, R.sub.21, or R.sub.22, wherein: R.sub.20 is --(CH.sub.2).sub.n -- where n is 2, 3, 4 or 5; R.sub.21 is --CH.sub.2 --CH.dbd.CH--CH.sub.2 --, --CH.sub.2 --C.dbd.--C--CH.sub.2 --, --CH.sub.2 --CH.dbd.CH--CH.sub.2 --CH.sub.2 --, --CH.sub.2 --CH.sub.2 --CH.dbd.CH--CH.sub.2 --, --CH.sub.2 --C--C--CH.sub.2 --CH.sub.2 --, or --CH.sub.2 --CH.sub.2 --C--C--CH.sub.2 --, the --CH.dbd.CH-- bond being cis or trans; R.sub.22 is R.sub.20 or R.sub.21 in which one or more carbon atoms of R.sub.20 or R.sub.21 are substituted by at least one C.sub.1 -C.sub.6 linear alkyl group, phenyl group or ##STR135## where Z.sub.1 is lower alkyl, --OH, lower alkoxy, --CF.sub.3, --NO.sub.2, --NH.sub.2 or halogen; R is hydrogen, lower alkyl, lower alkoxy, hydroxyl, carboxyl, chlorine, fluorine, bromine, iodine, amino, lower mono or dialkylamino, nitro, lower alkyl thio, trifluoromethoxy, cyano, acylamino, trifluoromethyl, trifluoroacetyl, aminocarbonyl, monoalkylaminocarbonyl, dialkylaminocarbonyl, formyl, --C(.dbd.O)-alkyl, --C(.dbd.O)--O-alkyl, --C(.dbd.O)-aryl, --C(.dbd.O)-heteroaryl, --CH(OR.sub.7)-alkyl, --C(.dbd.W)-alkyl, --C(.dbd.W)-aryl, or --C(.dbd.W)-heteroaryl alkyl is lower alkyl; in which aryl is phenyl or ##STR136## where R.sub.5 is hydrogen, lower alkyl, lower alkoxy, hydroxy, chlorine, fluorine, bromine, iodine, lower monoalkylamino, lower dialkylamino, nitro, cyano, trifluoromethyl, trifluoromethoxy; heteroaryl is ##STR137## Q.sub.3 is --O--, --S--, ##STR138## --CH.dbd.N--; W is CH.sub.2 or CHR.sub.8 or N--R.sub.9 ; R.sub.7 is hydrogen, lower alkyl, or acyl; R.sub.8 is lower alkyl; R.sub.9 is hydroxy, lower alkoxy, or --NHR.sub.10 ; and R.sub.10 is hydrogen, lower alkyl, C.sub.1 -C.sub.3 acyl, aryl, --C(.dbd.O)-aryl, or --C(.dbd.O)-heteroaryl, where aryl and heteroaryl are as defined above; and Q.sub.2 is --S--, --NH--, or --CH.sub.2 --; and m is 1,2, or3; with the proviso that X is not --O-- when Q.sub.2 is --CH.sub.2 --, Y is hydrogen, lower alkyl, lower alkoxy, hydroxy, or halogen, and p is 1 or 2; with the proviso that X is not --S-- when Q.sub.2 is --CH.sub.2 --, Y is hydrogen, halogen, lower alkyl, lower alkoxy, or hydroxy, p is 1 or 2, R is hydrogen, and m is 1; with the proviso that X is not --NH-- or ##STR139## when Q.sub.2 is --CH.sub.2 --, and Y is hydrogen, halogen, lower alkyl, lower alkoxy, hydroxy, nitro, amino, or trifluoromethyl; all geometric, optical, and stereoisomers thereof, or a pharmaceutically acceptable acid addition salt thereof. 2. The compound of claim 1, wherein X is --N(R.sub.2)--. 3. The compound of claim 2, wherein R.sub.2 is (C.sub.2 -C.sub.18)alkanoyl. 4. An antipsychotic composition, which comprises the compound of claim 1 in an amount sufficient to produce an antipsychotic effect, and a pharmaceutically acceptable carrier. 5. A method of treating psychoses, which comprises administering to a mammal a psychoses-treating amount of the compound of claim 1. 6. An analgesic composition, which comprises the compound of claim 1 in an amount sufficient to produce a pain-relieving effect, and a pharmaceutically acceptable carrier. 7. A method of alleviating pain, which comprises administering to a mammal a pain-relieving effective amount of the compound of claim 1. 8. A depot pharmaceutical composition, which comprises a pharmaceutically acceptable carrier and a therapeutically effective amount of the compound of claim 1, wherein the compound contains an acylated hydroxy group, or an acylated amino group. 9. The depot pharmaceutical composition of claim 8, wherein the hydroxy group is acylated with a (C.sub.4 -C.sub.18)alkanoyl group, or the amino group is acylated with a (C.sub.4 -C.sub.18) alkanoyl group or a (C.sub.4 -C.sub.18)alkoxycarbonyl group. 10. The composition of claim 8, which contains a pharmaceutically acceptable oil. 11. The composition of claim 10, wherein the oil is selected from the group consisting of coconut oil, peanut oil, sesame oil, cottonseed oil, corn oil, soybean oil, olive oil, and esters of fatty acids and polyfunctional alcohols. 12. The composition of claim 9, which contains a pharmaceutically acceptable oil. 13. The composition of claim 12, wherein the oil is selected from the group consisting of coconut oil, peanut oil, sesame oil, cottonseed oil, corn oil, soybean oil, olive oil, and esters of fatty acids and polyfunctional alcohols. 14. A method for providing a long acting antipsychotic effect, which comprises injecting into a mammal an amount of the composition of claim 8 sufficient to produce a long acting antipsychotic effect. 15. A method for providing a long acting antipsychotic effect, which comprises injecting into a mammal an amount of the composition of claim 9 sufficient to produce a long acting antipsychotic effect. 16. A method for providing a long acting antipsychotic effect, which comprises injecting into a mammal an amount of the composition of claim 13 sufficient to produce a long acting antipsychotic effect. 17. The compound of claim 1, which is 1-[4-[[3-[4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]propyl]thio]-3- methoxphenyl]ethanone and its pharmaceutically acceptable acid addition salts. 18. The compound of claim 1, which is 4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-[4-(2'-methoxyphenyl)]butylpiperidine maleate and its pharmaceutically acceptable acid addition salts. 19. The compound of claim 1, which is 1-[4-(4'-acetophenyl)butyl]-4-(6-fluoro-1,2-benzisoxazol-3-yl)piperidine and its pharmaceutically acceptable acid addition salts. 20. The compound of claim 1, which is 1-[4-[3-[4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]propylamino]-3-m ethoxyphenyl]ethanone and its pharmaceutically acceptable acid addition salts. 21. A pharmaceutical composition which comprises the compound of claim 1 and a pharmaceutically acceptable carrier therefor. 22. The compound 1-[4-[4-[1-(1,3-dithian-2-yl)ethyl]phenyl]butyl]-4-(6-fluoro-1,2-benzisoxa zol-3-yl)piperidine and its pharmaceutically acceptable acid addition salts. 23. A compound of the formula: ##STR140## wherein, X is --O--, --S--, --NH--, or ##STR141## R.sub.2 is selected from the group consisting of lower alkyl, aryl lower alkyl, aryl, cycloalkyl, aroyl, alkanoyl, alkoxycarbonyl, and phenysulfonyl groups; aryl is as defined hereinafter; p is 1 or 2; Y is hydrogen, lower alkyl, hydroxy, chlorine, fluorine, bromine, iodine, lower alkoxy, trifluoromethyl, nitro, or amino; R.sub.1 is --CR.sub.24 R.sub.27 --(CR.sub.23 R.sub.24).sub.n --CR.sub.24 R.sub.27 -- where n is 0, 1, 2, or 3; or --CHR.sub.24 CH.dbd.--CH--CHR.sub.24 --, --CHR.sub.24 --C.tbd.C--CHR.sub.24 --, --CHR.sub.24 --CH.dbd.CH--CR.sub.23 R.sub.24 --CHR.sub.24 --, --CHR.sub.24 --CR.sub.23 R.sub.24 --CH.dbd.CH--CHR.sub.24 --, --CHR.sub.24 --C.tbd.C--CR.sub.23 R.sub.24 --CHR.sub.24 --, or --CHR.sub.24 --CR.sub.23 R.sub.24 --C.tbd.C--CHR.sub.24 --, the --CH.dbd.CH-- bond being cis or trans; R.sub.23 is hydrogen, (C.sub.1 -C.sub.18)linear alkyl, phenyl, hydroxy, (C.sub.1 -C.sub.18)alkoxy, aryloxy, aryl(C.sub.1 -C.sub.18)alkyloxy, (C.sub.1 -C.sub.18)alkanoyloxy, hydroxy(C.sub.1 -C.sub.6)alkyl, (C.sub.1 -C.sub.18)alkoxy(C.sub.1 -C.sub.6)alkyl, aryl(C.sub.1 -C.sub.18)alkyloxy(C.sub.1 -C.sub.6)alkyl, (C.sub.1 -C.sub.18)alkanoyloxy(C.sub.1 -C.sub.6)alkyl, or ##STR142## where Z.sub.1 is lower alkyl, --OH, lower alkoxy, --CF.sub.3, --NO.sub.2, --NH.sub.2, or halogen, and p is as previously defined; and R.sub.24 is hydrogen, (C.sub.1 -C.sub.18)linear alkyl, phenyl, hydroxy(C.sub.1 -C.sub.6)alkyl, (C.sub.1 -C.sub.18)alkoxy(C.sub.1 -C.sub.6)alkyl, phenyl(C.sub.1 -C.sub.6)alkyloxy, aryl(C.sub.1 -C.sub.18)alkyloxy(C.sub.1 -C.sub.6)alkyl, (C.sub.1 -C.sub.18)alkanoyloxy(C.sub.1 -C.sub.6)alkyl, or ##STR143## where Z.sub.1 is as previously defined, and p is as previously defined; R.sub.27 is hydrogen or R.sub.24 and R.sub.27 taken together with the carbon to which they are attached form C.dbd.O or C.dbd.S; with the proviso that R.sub.23 is not hydrogen, (C.sub.1 -C.sub.18)linear alkyl, phenyl, or ##STR144## when R.sub.27 is hydrogen and R.sub.24 is hydrogen, (C.sub.1 -C.sub.18)linear alkyl, phenyl, or ##STR145## with the proviso that R.sub.24 is not hydrogen, (C.sub.1 -C.sub.18)linear alkyl, phenyl, or ##STR146## when R.sub.27 is hydrogen and n is 0, or when R.sub.27 is hydrogen and R.sub.23 is hydrogen, (C.sub.1 -C.sub.18)linear alkyl, phenyl, or ##STR147## or when R.sub.1 is --CHR.sub.24 --CH.dbd.CH--CHR.sub.24 -- or --CHR.sub.24 --C.tbd.C--CHR.sub.24 --; Q.sub.2 is --S--, --NH--, or --CH.sub.2 --; aryl is phenyl or ##STR148## wherein R.sub.5 is hydrogen, lower alkyl, lower alkoxy, hydroxy, chlorine, fluorine, bromine, iodine, lower monoalkylamino, lower dialkylamino, nitro, cyano, trifluoromethyl, or trifluoromethoxy; R is hydrogen, lower alkyl, lower alkoxy, hydroxyl, carboxyl, chlorine, fluorine, bromine, iodine, amino, lower mono- or dialkylamino, nitro, lower alkyl thio, trifluoromethoxy, cyano, acylamino, trifluoromethyl, trifluoroacetyl, aminocarbonyl, monoalkylaminocarbonyl, dialkylaminocarbonyl, formyl, --C(.dbd.O)-alkyl, --C(.dbd.O)--O-alkyl, --C(.dbd.O)-aryl, --C(.dbd.O)-heteroaryl, --CH(.dbd.OR.sub.7)-alkyl, --C(.dbd.W)-alkyl, --C(.dbd.W)-aryl, or --C(.dbd.W)-heteroaryl alkyl is (C.sub.1 -C.sub.18)alkyl; aryl is as previously defined; heteroaryl is ##STR149## Q.sub.3 is --O--, --S--, --NH--, or --CH.dbd.N--; W is CH.sub.2 or CHR.sub.8 or N--R.sub.9 ; R.sub.7 is hydrogen, alkyl, or alkanoyl; R.sub.8 is lower alkyl; R.sub.9 is hydroxy, alkoxy, or --NHR.sub.10 ; R.sub.10 is hydrogen, lower alkyl, (C.sub.1 -C.sub.18)acyl, aryl, --C(.dbd.O)-aryl or --C(.dbd.O)-heteroaryl, where aryl and heteroaryl are as defined above; m is 1,2,or3; and, any hydroxyl group attached to an aliphatic or aromatic carbon atom, or any primary or secondary nitrogen atom may be acylated with a (C.sub.4 -C.sub.18)alkanoyl group; in addition, any nitrogen atom may alternatively be acylated with a (C.sub.4 -C.sub.18)alkoxycarbonyl group; all geometric, optical, and stereoisomers thereof, or a pharmaceutically acceptable acid addition salt thereof. 24. The compound of claim 23, wherein X is ##STR150## 25. The compound of claim 24, wherein R.sub.2 is (C.sub.2 -C.sub.18)alkanoyl or (C.sub.1 -C.sub.18)alkoxycarbonyl. 26. An antipsychotic composition, which comprises the compound of claim 23 in an amount sufficient to produce an antipsychotic effect and a pharmaceutically acceptable carrier. 27. A method of treating psychoses, which comprises administering to a mammal a psychoses-treating amount of the compound of claim 23. 28. An analgesic composition, which comprises the compound of claim 23 in an amount sufficient to produce a pain-relieving effect and a pharmaceutically acceptable carrier. 29. A method of alleviating pain, which comprises administering to a mammal a pain-relieving effective amount of the compound of claim 23. 30. A depot pharmaceutical composition, which comprises a pharmaceutically acceptable carrier and a therapeutically effective amount of the compound of the formula: wherein, X is --O--, --S--, --NH--, or ##STR151## R.sub.2 is selected from the group consisting of lower alkyl, aryl lower alkyl, aryl, cycloalkyl, aroyl, alkanoyl, and phenylsulfonyl groups; wherein aryl is as defined hereinafter; p is 1 or 2; Y is hydrogen, lower alkyl, hydroxy, chlorine, fluorine, bromine, iodine, lower alkoxy, trifluoromethyl, nitro, or amino, when p is 1; Y is lower alkoxy, hydroxy or halogen when p is 2 and X is --O--; in which (R.sub.1) is R.sub.20, R.sub.21, or R.sub.22, wherein: R.sub.20 is --(CH.sub.2).sub.n -- where n is 2, 3, 4 or 5; R.sub.21 is --CH.sub.2 --CH.dbd.CH--CH.sub.2 --, --CH.sub.2 --CH.tbd.C--CH.sub.2 --, --CH.sub.2 --CH.dbd.CH--CH.sub.2 --CH.sub.2 --, --CH.sub.2 --CH.sub.2 --CH.dbd.CH--CH.sub.2 --, --CH.sub.2 --C.tbd.C--CH.sub.2 --CH.sub.2 --, or --CH.sub.2 --CH.sub.2 --C.tbd.C--CH.sub.2 --, the --CH.dbd.CH-- bond being cis or trans; R.sub.22 is R.sub.20 or R.sub.21 in which one or more carbon atoms of R.sub.20 or R.sub.21 are substituted by at least one C.sub.1 -C.sub.6 linear alkyl group, phenyl group or ##STR152## where Z.sub.1 is lower alkyl, --OH, lower alkoxy, --CF.sub.3, --NO.sub.2, --NH.sub.2 or halogen; R is hydrogen, lower alkyl, lower alkoxy, hydroxyl, carboxyl, chlorine, fluorine, bromine, iodine, amino, lower mono or dialkylamino, nitro, lower alkyl thio, trifluoromethoxy, cyano, acylamino, trifluoromethyl, trifluoroacetyl, aminocarbonyl, monoalkylaminocarbonyl, dialkylaminocarbonyl, formyl, --C(.dbd.O)-alkyl, --C(.dbd.O)--O-alkyl, --C(.dbd.O)-aryl, --C(.dbd.O)-heteroaryl, --CH(OR.sub.7)-alkyl, --C(.dbd.W)-alkyl, --C(.dbd.W)-aryl, or --C(.dbd.W)-heteroaryl alkyl is lower alkyl; in which aryl is phenyl or ##STR153## where R.sub.5 is hydrogen, lower alkyl, lower alkoxy, hydroxy, chlorine, fluorine, bromine, iodine, lower monoalkylamino, lower dialkylamino, nitro, cyano, trifluoromethyl, trifluoromethoxy; heteroaryl is ##STR154## Q.sub.3 is --O--, --S--, --NH--, --CH.dbd.N--; W is CH.sub.2 or CHR8 or N--R.sub.9 ; R.sub.7 is hydrogen, lower alkyl, or acyl; R.sub.8 is lower alkyl; R.sub.9 is hydroxy, lower alkoxy, or --NHR.sub.10 ; and R.sub.10 is hydrogen, lower alkyl, C.sub.1 -C.sub.3 acyl, aryl, --C(.dbd.O)-aryl, or --C(.dbd.O)-heteroaryl, where aryl and heteroaryl are as defined above; and Q.sub.2 is --S--, --NH--, or --CH.sub.2 --; and m is 1,2,or3; and, any hydroxyl group attached to an aliphatic or aromatic carbon atom, or any primary or secondary nitrogen atom may be acylated with a (C.sub.4 -C.sub.18)alkanoyl group; in addition, any nitrogen atom may alternatively be acylated with a (C.sub.4 -C.sub.18)alkoxycarbonyl group; with the proviso that X is not --O-- when Q.sub.2 is --CH.sub.2 --, Y is hydrogen, lower alkyl, lower alkoxy, hydroxy, or halogen, and p is 1 or 2; with the proviso that X is not --S-- when Q.sub.2 is --CH.sub.2 --, Y is hydrogen, halogen, lower alkyl, lower alkoxy, or hydroxy, p is 1 or 2, R is hydrogen, and m is 1; with the proviso that X is not --NH-- or ##STR155## when Q.sub.2 is --CH.sub.2 --, and Y is hydrogen, halogen, lower alkyl, lower alkoxy, hydroxy, nitro, amino, or trifluoromethyl; all geometric, optical, and stereoisomers thereof, or a pharmaceutically acceptable acid addition salt thereof. 31. The depot pharmaceutical composition of claim 30, wherein the hydroxy group is acylated with a (C.sub.4 -C.sub.18)alkanoyl group, or the amino group is acylated with a (C.sub.4 -C.sub.18)alkanoyl group or a (C.sub.4 -C.sub.18)alkoxycarbonyl group. 32. The composition of claim 30, which contains a pharmaceutically acceptable oil. 33. The composition of claim 32, wherein the oil is selected from the group consisting of coconut oil, peanut oil, sesame oil, cottonseed oil, corn oil, soybean oil, olive oil, and esters of fatty acids and polyfunctional alcohols. 34. The composition of claim 31, which contains a pharmaceutically acceptable oil. 35. The composition of claim 34, wherein the oil is selected from the group consisting of coconut oil, peanut oil, sesame oil, cottonseed oil, corn oil, soybean oil, olive oil, and esters of fatty acids and polyfunctional alcohols. 36. A method for providing a long acting antipsychotic effect, which comprises injecting into a mammal an amount of the composition of claim 30 sufficient to produce a long acting antipsychotic effect. 37. A method for providing a long acting antipsychotic effect, which comprises injecting into a mammal an amount of the composition of claim 31 sufficient to produce a long acting antipsychotic effect. 38. A method for providing a long acting antipsychotic effect, which comprises injecting into a mammal an amount of the composition of claim 35 sufficient to produce a long acting antipsychotic effect. 39. A compound of the formula: ##STR156## wherein, X is --O--, --S--, --NH--, or ##STR157## R.sub.2 is selected from the group consisting of lower alkyl, aryl lower alkyl, aryl, cycloalkyl, aroyl, alkanoyl, alkoxycarbonyl, and phenylsulfonyl groups; aryl is as defined hereinafter; p is 2; Y is lower alkyl, hydroxy, chlorine, fluorine, bromine, iodine, lower alkoxy, trifluoromethyl, nitro, or amino when X is --S--, --NH--, or --N(R.sub.2)--; Y is lower alkyl, trifluoromethyl, nitro, or amino when X is --O--; R.sub.1 is --CR.sub.24 R.sub.27 --(CR.sub.23 R.sub.24).sub.n --CR.sub.24 R.sub.27 --, where n is 0, 1, 2 or 3; or --CHR.sub.24 CH.dbd.CH--CHR.sub.24 --, --CHR.sub.24 --C.tbd.C--CHR.sub.24 --, --CHR.sub.24 --CH.dbd.CH--CR.sub.23 R.sub.24 --CHR.sub.24 --, --CHR.sub.24 --CR.sub.23 R.sub.24 --CH.dbd.CH--CHR.sub.24 --, --CHR.sub.24 --C.tbd.C--CR.sub.23 R.sub.24 --CHR.sub.24 --, or --CHR.sub.24 --CR.sub.23 R.sub.24 --C.tbd.C--CHR.sub.24 --, the --CH.dbd.CH-- bond being cis or trans; R.sub.23 is hydrogen, (C.sub.1 -C.sub.18) linear alkyl, phenyl, hydroxy, (C.sub.1 -C.sub.18)alkoxy, aryloxy, aryl(C.sub.1 -C.sub.18)alkyloxy, (C.sub.1 -C.sub.18)alkanoyloxy, hydroxy(C.sub.1 -C.sub.6)alkyl, (C.sub.1 -C.sub.18)alkoxy(C.sub.1 -C.sub.6)alkyl, aryl(C.sub.1 -C.sub.18)alkyloxy(C.sub.1 -C.sub.6)alkyl, (C.sub.1 -C.sub.18)alkanoyloxy(C.sub.1 -C.sub.6)alkyl or ##STR158## where Z.sub.1 is lower alkyl, --OH, lower alkoxy, --CF.sub.3, --NO.sub.2, --NH.sub.2, or halogen, and p is as previously defined, wherein aryl is as defined hereinafter; R.sub.24 is hydrogen, (C.sub.1 -C.sub.18)linear alkyl, phenyl, hydroxy(C.sub.1 -C.sub.6)alkyl, (C.sub.1 -C.sub.18)alkoxy(C.sub.1 -C.sub.6)alkyl, phenyl(C.sub.1 -C.sub.6)alkyloxy, aryl(C.sub.1 -C.sub.18)alkyloxy(C.sub.1 -C.sub.6)alkyl, (C.sub.1 -C.sub.18)alkanoyloxy(C.sub.1 -C.sub.6)alkyl, or ##STR159## where Z.sub.1 and p are as previously defined, wherein aryl is as defined hereinafter; R.sub.27 is hydrogen or R.sub.24 and R.sub.27 taken together with the carbon to which they are attached form C.dbd.O or C.dbd.S; Q.sub.2 is --S--, --NH--, or --CH.sub.2 --; aryl is phenyl or ##STR160## wherein R.sub.5 is hydrogen, lower alkyl, lower alkoxy, hydroxy, chlorine, fluorine, bromine, iodine, lower monoalkylamino, lower dialkylamino, nitro, cyano, trifluoromethyl, or trifluoromethoxy; R is hydrogen, lower alkyl, lower alkoxy, hydroxyl, carboxyl, chlorine, fluorine, bromine, iodine, amino, lower mono- or dialkylamino, nitro, lower alkyl thio, trifluoromethoxy, cyano, acylamino, trifluoromethyl, trifluoroacetyl, aminocarbonyl, monoalkylaminocarbonyl, dialkylaminocarbonyl, formyl, --C(.dbd.O)-alkyl, --C(.dbd.O)--O-alkyl, --C(.dbd.O)-aryl, --C(.dbd.O)--heteroaryl, --CH(OR.sub.7)-alkyl, --C(.dbd.W)-alkyl, --C(.dbd.W)-aryl, or --C(.dbd.W)-heteroaryl alkyl is (C.sub.1 -C.sub.18)alkyl; aryl is as previously defined; heteroaryl is ##STR161## Q.sub.3 is --O--, --S--, --NH--, or --CH.dbd.N--; W is CH.sub.2 or CHR.sub.8 or N--R.sub.9 ; R.sub.7 is hydrogen, alkyl, or alkanoyl; R.sub.8 is lower alkyl; R.sub.9 is hydroxy, alkoxy, or --NHR.sub.10 ; R.sub.10 is hydrogen, lower alkyl, (C.sub.1 -C.sub.18)acyl, aryl, --C(.dbd.O)--aryl or --C(.dbd.O)-heteroaryl, where aryl and heteroaryl are as defined above; m is 1,2,or3; and, any hydroxyl group attached to an aliphatic or aromatic carbon atom, or any primary or secondary nitrogen atom may be acylated with a (C.sub.4 -C.sub.18)alkanoyl group; in addition, any nitrogen atom may alternatively be acylated with a (C.sub.4 -C.sub.18)alkoxycarbonyl group; with the exclusion of a compound wherein X is --NH-- or --N(R.sub.2)--, Y is hydrogen, halogen, lower alkyl, lower alkoxy, hydroxy, nitro, amino, or trifluoromethyl, and Q.sub.2 is --CH.sub.2 --; with the exclusion of a compound wherein X is --O--, Q.sub.2 is --CH.sub.2 --, Y is hydrogen, lower alkyl, lower alkoxy, hydroxy, or halogen, and p is 1 or 2; with the exclusion of a compound wherein X is --S--, Q.sub.2 is --CH.sub.2 --, Y is hydrogen, halogen, lower alkyl, lower alkoxy, or hydroxy, p is 1 or 2, R is hydrogen, and m is 1; all geometric, optical, and stereoisomers thereof, or a pharmaceutically acceptable acid addition salt thereof. 40. The compound of claim 39, wherein X is ##STR162## 41. The compound of claim 39, wherein R.sub.2 is (C.sub.2 -C.sub.18)alkanoyl or (C.sub.1 -C.sub.18)alkoxycarbonyl. 42. An antipsychotic composition, which comprises the compound of claim 39 in an amount sufficient to produce an antipsychotic effect and a pharmaceutically acceptable carrier. 43. A method of treating psychoses, which comprises administering to a mammal a psychoses-treating amount of the compound of claim 39. 44. An analgesic composition, which comprises the compound of claim 39 in an amount sufficient to produce a pain-relieving effect and a pharmaceutically acceptable carrier. 45. A method of alleviating pain, which comprises administering to a mammal a pain-relieving effective amount of the compound of claim 39. 46. A depot pharmaceutical composition, which comprises a pharmaceutically acceptable carrier and a therapeutically effective amount of the compound of claim 39, wherein the compound contains an acylated hydroxy group, or an acylated amino group. 47. The depot pharmaceutical composition of claim 46, wherein the hydroxy group is acylated with a (C.sub.4 -C.sub.18)alkanoyl group, or the amino group is acylated with a (C.sub.4 -C.sub.18)alkanoyl group or a (C.sub.4 -C.sub.18)alkoxycarbonyl group. 48. The composition of claim 46, which contains a pharmaceutically acceptable oil. 49. The composition of claim 48, wherein the oil is selected from the group consisting of coconut oil, peanut oil, sesame oil, cottonseed oil, corn oil, soybean oil, olive oil, and esters of fatty acids and polyfunctional alcohols. 50. The composition of claim 47, which contains a pharmaceutically acceptable oil. 51. The composition of claim 50, wherein the oil is selected from the group consisting of coconut oil, peanut oil, sesame oil, cottonseed oil, corn oil, soybean oil, olive oil, and esters of fatty acids and polyfunctional alcohols. 52. A method for providing a long acting antipsychotic effect, which comprises injecting into a mammal an amount of the composition of claim 46 sufficient to produce a long acting antipsychotic effect. 53. A method for providing a long acting antipsychotic effect, which comprises injecting into a mammal an amount of the composition of claim 47 sufficient to produce a long acting antipsychotic effect. 54. A method for providing a long acting antipsychotic effect, which comprises injecting into a mammal an amount of the composition of claim 51 sufficient to produce a long acting antipsychotic effect.